We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
51
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.05M 0.2%
+1,000
New +$63.4K
ACAD icon
52
PUT
Acadia Pharmaceuticals
ACAD
$4.25B
$3.9M 0.19%
1,393
-2,782
-67% -$60.7K
ALXN
53
DELISTED
Alexion Pharmaceuticals
ALXN
$3.88M 0.19%
27,856
+25,900
+1,324% +$3.8M
PGEN icon
54
Precigen
PGEN
$1.93B
$3.79M 0.19%
112,914
+101,820
+918% +$3.21M
NVIV
55
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$3.79M 0.19%
+29
New +$3.11M
CELG
56
CALL
DELISTED
Celgene Corp
CELG
$3.75M 0.19%
313
– –
REGN icon
57
CALL
Regeneron Pharmaceuticals
REGN
$68.8B
$3.71M 0.19%
+103
New +$42.4K
CLVS
58
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.58M 0.18%
1,862
+1,612
+645% +$34.1K
PGEN icon
59
PUT
Precigen
PGEN
$1.93B
$3.44M 0.17%
1,023
+888
+658% +$28K
LUMO
60
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.37M 0.17%
206
-42
-17% -$8.51K
ITCI
61
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.36M 0.17%
1,208
+688
+132% +$22.9K
VXZ
62
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$3.26M 0.16%
75,000
-56,283
-43% -$2.75M
RGNX icon
63
Regenxbio
RGNX
$623M
$3.24M 0.16%
300,329
+183,469
+157% +$2.35M
SAGE
64
DELISTED
Sage Therapeutics
SAGE
$3.21M 0.16%
100,000
+91,877
+1,131% +$3.23M
INDP icon
65
Indaptus Therapeutics
INDP
$348M
$2.95M 0.15%
319
+20
+7% +$186K
FOLD
66
PUT
DELISTED
Amicus Therapeutics
FOLD
$2.94M 0.15%
3,485
-14
-0.4% -$99
PRTK
67
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.92M 0.15%
192,322
+69,709
+57% +$1.07M
ADMS
68
DELISTED
Adamas Pharmaceuticals
ADMS
$2.89M 0.14%
+199,890
New +$3.37M
ESRX
69
DELISTED
Express Scripts Holding Company
ESRX
$2.84M 0.14%
+41,311
New +$2.97M
ITCI
70
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.84M 0.14%
1,020
+920
+920% +$30.7K
ONCS
71
DELISTED
OncoSec Medical Incorporated
ONCS
$2.83M 0.14%
5,052
-513
-9% -$219K
ENLV icon
72
Enlivex Ltd
ENLV
$70.7M
$2.82M 0.14%
+1,890
New +$3.37M
AKRX
73
PUT
DELISTED
Akorn Inc
AKRX
$2.81M 0.14%
+1,194
New +$31.4K
ADVM
74
DELISTED
Adverum Biotechnologies
ADVM
$2.79M 0.14%
54,063
+34,550
+177% +$1.93M
NBIX icon
75
Neurocrine Biosciences
NBIX
$17.7B
$2.77M 0.14%
+70,000
New +$2.78M
1 2
3
4 5

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.